FDA Clears Padeliporfin VTP Ph 1 Clinical Program in Peripheral Lung Cancer

Barak Palatchi, CEO of ImPact Biotech, said, “We are delighted to receive FDA clearance to proceed with our planned clinical program for Padeliporfin VTP in Lung Cancer, further validating ImPact’s technology and the potential benefits our product could bring to patients with Peripheral Lung Cancer. Our strategy, focusing Padeliporfin VTP therapy on patients with limited treatment options, is proceeding according to our ambitious plan, with NSCLC as one of its major pillars. We are planning to demonstrate that Padeliporfin VTP offers a safe and effective treatment that will provide patients and their physicians with an additional therapy platform to target the disease. We are looking forward to exploring the possibility of offering Padeliporfin VTP to more patients coping with life threatening cancers.”

Share:

More News

Taiho Oncology, Inc. completed a New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA) for zipalertinib in combination with platinum-based chemotherapy for the treatment of patients with previously untreated, locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20

“This collaboration reflects our conviction that atebimetinib has the potential to become an essential backbone therapy in a broad range of combinations across MAPK-driven cancers,” said Ben Zeskind, Immuneering CEO and co-founder. “Atebimetinib’s unique tolerability profile and broad activity make it well suited to combine with a wide range of

“These final updated results provide continued evidence of the potential for γδ T cell therapies to drive activity and improve outcomes for patients,” said William Ho, CEO and co-founder of IN8bio. “The clinical outcomes and observed activity are supported by our correlative analysis, including histopathology, demonstrating the expansion and persistence

“Patients with RAS-mutated mCRC have no first-line therapies specifically approved for their disease, and Fast Track designation reflects the potential of onvansertib to address this serious unmet need,” said Mani Mohindru, PhD, President and Chief Executive Officer of Cardiff Oncology. “Our randomized Phase 2 data give us confidence that onvansertib